HomeCompareSTMM vs ARCC

STMM vs ARCC: Dividend Comparison 2026

STMM yields 3333.33% · ARCC yields 10.82%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 STMM wins by $1244041712890.37M in total portfolio value
10 years
STMM
STMM
● Live price
3333.33%
Share price
$0.06
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1244041712890.40M
Annual income
$1,174,716,366,071,938,000.00
Full STMM calculator →
ARCC
Ares Capital Corporation
● Live price
10.82%
Share price
$17.74
Annual div
$1.92
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$1.16
Full ARCC calculator →

Portfolio growth — STMM vs ARCC

📍 STMM pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSTMMARCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, STMM + ARCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
STMM pays
ARCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

STMM
Annual income on $10K today (after 15% tax)
$283,333.33/yr
After 10yr DRIP, annual income (after tax)
$998,508,911,161,147,300.00/yr
ARCC
Annual income on $10K today (after 15% tax)
$919.95/yr
After 10yr DRIP, annual income (after tax)
$0.99/yr
At 15% tax rate, STMM beats the other by $998,508,911,161,147,300.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of STMM + ARCC for your $10,000?

STMM: 50%ARCC: 50%
100% ARCC50/50100% STMM
Portfolio after 10yr
$622020856445.21M
Annual income
$587,358,183,035,969,000.00/yr
Blended yield
94.43%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARCC right now

STMM
No analyst data
ARCC
Analyst Ratings
24
Buy
7
Hold
Consensus: Buy
Price Target
$21.88
+23.3% upside vs current
Range: $21.00 — $23.00
Altman Z
0.8
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

STMM buys
0
ARCC buys
0
No recent congressional trades found for STMM or ARCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSTMMARCC
Forward yield3333.33%10.82%
Annual dividend / share$2.00$1.92
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$1244041712890.40M$24.5K
Annual income after 10y$1,174,716,366,071,938,000.00$1.16
Total dividends collected$1239274250481.68M$1.1K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: STMM vs ARCC ($10,000, DRIP)

YearSTMM PortfolioSTMM Income/yrARCC PortfolioARCC Income/yrGap
1← crossover$344,033$333,333.33$11,381$541.15+$332.7KSTMM
2$11,085,665$10,717,549.33$12,621$284.08+$11.07MSTMM
3$334,616,633$322,754,971.08$13,827$145.31+$334.60MSTMM
4$9,462,934,690$9,104,894,892.71$15,062$73.43+$9462.92MSTMM
5$250,766,259,005$240,640,918,887.41$16,364$36.89+$250766.24MSTMM
6$6,228,082,462,189$5,959,762,565,053.11$17,757$18.49+$6228082.44MSTMM
7$144,998,525,500,125$138,334,477,265,582.72$19,258$9.25+$144998525.48MSTMM
8$3,165,074,899,913,431$3,009,926,477,628,297.00$20,880$4.63+$3165074899.89MSTMM
9$64,790,043,755,570,470$61,403,413,612,663,110.00$22,636$2.32+$64790043755.55MSTMM
10$1,244,041,712,890,398,500$1,174,716,366,071,938,000.00$24,539$1.16+$1244041712890.37MSTMM

STMM vs ARCC: Complete Analysis 2026

STMMStock

Stemcell Holdings, Inc., through its subsidiary, Stemcell Co., Ltd., engages in the regenerative medicine-related business. It provides technical assistance services to the culturing, storing, and delivery of stem cells; and administrative and consulting services to clinics. The company offers two different options for stem cell regenerative therapy, including autologous adipose derived mesenchymal stem cells and natural killer cells. It also provides coordination services to facilitate its stem cell culturing business, which comprise the introduction of patients to clinics, arranging patients' schedules, and translating between patients and clinics due to language barriers. In addition, Stemcell Holdings, Inc. offers Internet marketing services through search engine optimization for clinics; and property and equipment rental services. The company was formerly known as Perfect Acquisition, Inc., and changed its name to Stemcell Holdings, Inc. in January 2016. Stemcell Holdings, Inc. was founded in 2015 and is based in Tokyo, Japan. as of May 2, 2016, Stemcell Holdings, Inc. operates as a subsidiary of Primavera Singa Pte Ltd.

Full STMM Calculator →

ARCCBDC

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.

Full ARCC Calculator →
📬

Get this STMM vs ARCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

STMM vs SCHDSTMM vs JEPISTMM vs OSTMM vs KOSTMM vs MAINSTMM vs HTGCSTMM vs GBDCSTMM vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.